Litcius/Paper detail

Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non–Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L)

Naoki Haratake, Hidetoshi Hayashi, Mototsugu Shimokawa, Yusuke Nakano, Koichi Azuma, Masahide Oki, Keiichi Ota, Hiroshige Yoshioka, Tomohiro Sakamoto, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Takashi Seto

2021Clinical Lung Cancer26 citationsDOI

Topics & Concepts

OsimertinibErlotinibMedicineRamucirumabLung cancerInternal medicineOncologyMutationClinical trialCancer researchEpidermal growth factor receptorCancerGeneticsGeneBiologyLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non–Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L) | Litcius